A group of attorneys general from 26 states and territories are urging the Biden administration to provide access to FDA-approved Alzheimer's treatments, as CMS continues to deny Medicare beneficiaries living with early Alzheimer's access to these treatments. The Alzheimer's Association and Alzheimer's Impact Movement are advocating for access to these treatments and are grateful for the attorneys general's support.